Design and evaluation of mucoadhesive microemulsion for neuroprotective effect of ibuprofen following intranasal route in the MPTP mice model

Mandal, Sujit; Mandal, Snigdha Das; Chuttani, Krishna; Sawant, Krutika; Subudhi, Bharat Bhusan

doi:10.3109/03639045.2015.1135936

Cited by 14 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of the drug delivery system were evaluated on an acute SCI rat model by hindlimb motor function, histopathological evaluation, immunohistochemistry and the assessment of the level of the inflammatory cytokine (tumor necrosis factor alpha, TNF-α). Furthermore, ibuprofen was chosen as the biologically active carboxylic acids, which could surmount axon growth restrictions from myelin and proteoglycans and stimulate a significant neurite growth in the cultured dorsal root ganglion neurons [ 30 ]. It has a great potential in the synergetic effect treatment for spinal cord injury.…”

Section: Introductionmentioning

confidence: 99%

Synthesis of methylprednisolone loaded ibuprofen modified dextran based nanoparticles and their application for drug delivery in acute spinal cord injury

Jiang

Cui

et al. 2017

Oncotarget

View full text Add to dashboard Cite

To improve the therapeutic efficacy of spinal cord injury (SCI), the methylprednisolone was incorporated into nanoparticles based on the ibuprofen modified dextran. The ibuprofen modified dextran was synthesized using a direct esterification linkage between the carboxylic acids of hydrophobic drug and the hydroxyl groups of the polymer backbone. The morphology of methylprednisolone loaded nanoparticles was evaluated by transmission electron microscopy (TEM) and dynamic light scattering (DLS). The therapeutic efficacy of the prepared nanoparticles on the acute SCI model rats was assessed. It is demonstrated that methylprednisolone loaded ibuprofen modified dextran based nanoparticles (MP-loaded NPs) could promote the recovery of neurological deficits, enhance growth of neurons, decrease degeneration of injuried neurons and reduce the tissue tumor necrosis factor alpha (TNF-α) levels significantly in the SCI rats. Subsequently, the study indicates that synthesis of methylprednisolone loaded ibuprofen modified dextran based nanoparticles has a great potential in the synergetic effect treatment for spinal cord injury and nanoparticles based drug delivery system will become a powerful weapon of human conquest of disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Synthesis of methylprednisolone loaded ibuprofen modified dextran based nanoparticles and their application for drug delivery in acute spinal cord injury

Jiang

Cui

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Studies have reported the therapeutic potentiality of anti-inflammatory drugs, like minocycline, dexamethasone, ibuprofen, celecoxib, salicylic acid, etc., in the treatment of PD. [95][96][97][98]171 The application of nanovesicular carriers in delivery of these anti-inflammatory drugs has also been explored in recent times. 172,173 Not much progress has been observed in this arena; however, in one study dexamethasone-loaded CD163+ ligand-tagged liposomes were found to exhibit sustained delivery of the loaded cargo to the immune cell population in the brain of PD rodents, increased striatal DA content, ameliorated dopaminergic neuron loss in SN, and improved motor performances.…”

Section: Nanovesicle-aided Delivery Of Drugs Targeting Dopamine Deple...mentioning

confidence: 99%

“…), ,, MAO-B inhibitors (e.g., selegiline and rasagiline), , and COMT inhibitors (e.g., entacapone and tolcapone) have the potential to keep a raised level of dopamine in the brain and hence are recommended as adjunctive to L-DOPA therapy. Preclinical and clinical studies provided evidence of immense therapeutic benefits of neurotrophins (BDNF and GDNF), , antioxidants (vitamin E, CoQ10, mitoQ), ,, anti-inflammatory drugs (dexamethasone, ibuprofen, celecoxib, minocycline), − α-synuclein inhibitors (anti-α-synuclein ASO, shRNA, aptamer, NPT200-11), ,− and compounds targeting the lysosome–proteosome dysfunction (ambroxol, nilotinib, Hsp therapy, beclin, and parkin gene therapy) − in exhibiting anti-PD effects. Moreover, numerous phyto-compounds (curcumin, resveratrol, quercetin, 7,8-dihydroxyflavone, lycopene) ,,− have also been extensively explored and have shown remarkable potential against PD.…”

Section: Present Day Anti-pd Therapeutic Considerations and Their Lim...mentioning

confidence: 99%

Combating Dopaminergic Neurodegeneration in Parkinson’s Disease through Nanovesicle Technology

Roy

Paul²,

Bhattacharya

et al. 2023

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Parkinson's disease (PD) is characterized by dopaminergic neurodegeneration, resulting in dopamine depletion and motor behavior deficits. Since the discovery of L-DOPA, it has been the most prescribed drug for symptomatic relief in PD, whose prolonged use, however, causes undesirable motor fluctuations like dyskinesia and dystonia. Further, therapeutics targeting the pathological hallmarks of PD including αsynuclein aggregation, oxidative stress, neuroinflammation, and autophagy impairment have also been developed, yet PD treatment is a largely unmet success. The inception of the nanovesicle-based drug delivery approach over the past few decades brings add-on advantages to the therapeutic strategies for PD treatment in which nanovesicles (basically phospholipid-containing artificial structures) are used to load and deliver drugs to the target site of the body. The present review narrates the characteristic features of nanovesicles including their blood−brain barrier permeability and ability to reach dopaminergic neurons of the brain and finally discusses the current status of this technology in the treatment of PD. From the review, it becomes evident that with the assistance of nanovesicle technology, the therapeutic efficacy of anti-PD pharmaceuticals, phyto-compounds, as well as that of nucleic acids targeting α-synuclein aggregation gained a significant increment. Furthermore, owing to the multiple drug-carrying abilities of nanovesicles, combination therapy targeting multiple pathogenic events of PD has also found success in preclinical studies and will plausibly lead to effective treatment strategies in the near future.

show abstract

“…Florence et al [146] published the results of a study aiming at the formulation of an intranasal, mucoadhesive oil-water (O/W) microemulsion for nose-to-brain delivery of clobazam, an anticonvulsant benzodiazepine drug used for the treatment of different epilepsy types and applied in some psychiatric disorders manifesting with anxiety. The obtained microemulsion contained Capmul ® MCM as the oil phase and the combination of polyoxyethylene-6-caprylic and capric glycerides (Acconan ® CC6) and Tween ® 20 as the Mandal et al [145] investigated intranasal mucoadhesive microemulsion with ibuprofen as neuroprotective agent in Parkinson's disease. Capmul ® MCM, Accenon ® CC, and Transcutol ® were selected as oil, surfactant, and co-surfactant, respectively.…”

Section: Epilepsymentioning

confidence: 99%

Microemulsion-Based Media in Nose-to-Brain Drug Delivery

et al. 2021

View full text Add to dashboard Cite

Nose-to-brain drug delivery has recently attracted enormous attention as an alternative to other delivery routes, including the most popular oral one. Due to the unique anatomical features of the nasal cavity, drugs administered intranasally can be delivered directly to the central nervous system. The most important advantage of this approach is the ability to avoid the blood–brain barrier surrounding the brain and blocking the entry of exogenous substances to the central nervous system. Moreover, selective brain targeting could possibly avoid peripheral side effects of pharmacotherapy. The challenges associated with nose-to-brain drug delivery are mostly due to the small volume of the nasal cavity and insufficient drug absorption from nasal mucosa. These issues could be minimized by using a properly designed drug carrier. Microemulsions as potential drug delivery systems offer good solubilizing properties and the ability to enhance drug permeation through biological membranes. The aim of this review is to summarize the current status of the research focused on microemulsion-based systems for nose-to-brain delivery with special attention to the most extensively investigated neurological and psychiatric conditions, such as neurodegenerative diseases, epilepsy, and schizophrenia.

show abstract

Design and evaluation of mucoadhesive microemulsion for neuroprotective effect of ibuprofen following intranasal route in the MPTP mice model

Cited by 14 publications

References 29 publications

Synthesis of methylprednisolone loaded ibuprofen modified dextran based nanoparticles and their application for drug delivery in acute spinal cord injury

Synthesis of methylprednisolone loaded ibuprofen modified dextran based nanoparticles and their application for drug delivery in acute spinal cord injury

Combating Dopaminergic Neurodegeneration in Parkinson’s Disease through Nanovesicle Technology

Microemulsion-Based Media in Nose-to-Brain Drug Delivery

Contact Info

Product

Resources

About